Drugs / BCMA targeted prime CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04776330 | Mar 2021 → Dec 2026 expected | plasma cell myeloma | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA targeted prime CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04776330 ↗ |
| Modality | Cell therapy | “BCMA targeted prime CAR-T cells” NCT04776330 ↗ |